Emerging Trends Influencing The Growth Of The COVID-19 Current Therapy Market: Exploring Convalescent Plasma Therapy As An Experimental Approach For COVID-19 Treatment

The COVID-19 Current Therapy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the COVID-19 Current Therapy Market Size Expected to Be by 2034?
The market size for current COVID-19 therapy has faced a significant plunge in the recent past. It is projected to fall from "$5.87 billion in 2024 to $2.35 billion in 2025 with a compound annual growth rate (CAGR) of -60.0%. This sharp downturn in the earlier period can be connected to factors like the scarcity of treatment alternatives, inconsistent treatment effectiveness, interruptions in the supply chain, promptly changing scientific understanding, and the appearance of new variants.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3247

What Are the Emerging Segments Within the COVID-19 Current Therapy Market?
The COVID-19 current therapy market covered in this report is segmented -

1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others
2) By Route Of Administration: Oral, Intravenous
3) By End-User: Hospitals, Clinics, Home Care, Others

Subsegments:
1) By Antiviral: Remdesivir, Oseltamivir, Favipiravir, Nirmatrelvir Or ritonavir (Paxlovid)
2) By Monoclonal Antibodies: Bamlanivimab, Casirivimab Or Imdevimab (REGEN-COV), Sotrovimab, Etesevimab
3) By Corticosteroid: Dexamethasone, Hydrocortisone, Prednisone
4) By Supplements: Vitamin D, Vitamin C, Zinc, Quercetin
5) By Antimalarial: Hydroxychloroquine, Chloroquine
6) By Interferons and Interleukin Inhibitors: Interferon beta-1a, Interleukin-6 inhibitors
7) By Other Anti-Infective Drugs: Antibiotics, Antifungal agents
8) By Others: Other experimental therapies, Alternative treatments not categorized above

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp

What Long-Term Drivers Are Shaping COVID-19 Current Therapy Market Trends?
The pandemic COVID-19 has played a significant role in boosting the COVID-19 current therapy market. A global pandemic status was accorded to the outbreak by the World Health Organization (WHO). For example, as of August 2022, the WHO, a specialized United Nations agency originated in Switzerland, reported that the worldwide tally of COVID-19 cases had climbed to 581.8 million. Given that there's no officially sanctioned medication for COVID-19, the call for repurposed drugs, employed in coronatherapy, has witnessed a marked increase. Amidst a global drug shortage brought about by the disease, drug companies are increasing their production capacities to cater to global needs. Furthermore, the FDA has launched the COVID-19 Treatment Acceleration Program (CTAP), a special emergency initiative aimed at fast-tracking the development and availability of potential COVID-19 therapies for patients.

Who Are the Top Competitors in Key COVID-19 Current Therapy Market Segments?
Major companies operating in the COVID-19 current therapy market include Gilead Sciences, Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals, Inc., Mylab Discovery Solutions, Kalbe Farma, He Qi Group Foundation, Beijing Jinwofu Bioengineering Technology Company, Zhejiang Orient Gene Biotech Co. Ltd, Transasia Bio Medicals, Vanguard Diagnostics, HLL Lifecare Limited, Voxtur Bio Ltd, Biocryst Pharma, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., LAB-CARE Diagnostics, ImmunoScience, CPC Diagnostics, Sysmex Corporation, Atomo Diagnostics, Cellmid Limited, Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Hunan Lituo Biotechnology, Hangzhou Biotest Biotech, AmonMed Biotechnology, Getein Biotech, Beijing Tigsun Diagnostics, Vivacheck Lab, Seegene, SD Biosensor, Fujirebio, Siemens Healthcare Pte. Ltd., Senova, LetsGetChecked, Omega Diagnostics, Abingdon Health, Babylon, Motologic, F. Hoffmann-La Roche Ltd., Novacyt Group, AstraZeneca, Pfizer, Zentiva, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Amgen and AdaptiveBiotechnologies, BioNtech, Cytodyn, Heat biologics, Johnson&Johnson, Takeda pharmaceuticals, Vaxart, Vir Biotechnology, Victory Square Health, Abbott Molecular Inc., ACRO Biotech, Advagen Biotech Ltd, BD, Boditech Med, Inc., Cellex Inc., CerTest Biotec, S.L., Hi Technologies, BATM, BioMedomics Quant Lease, CapeBio, Astel Diagnostics, Canary Health Technologies, Thermo Fisher Scientific

What COVID-19 Current Therapy Market Trends Are Gaining Traction Across Different Segments?
Convalescent Plasma Therapy, an experimental treatment approach, is being used for COVID-19 patients. This kind of treatment involves the use of convalescent plasma (CP), i.e., the blood plasma from patients who have recovered from the illness. In this form of passive antibody therapy, blood plasma collected from patients who have overcome the disease is given to those severely ill to mitigate the virulence and relieve clinical symptoms. The blood plasma from patients who have recovered from COVID-19 contains antibodies capable of combatting the infection. As per the directives provided by the FDA, Convalescent Plasma Therapy is suggested as an experimental product during a public health crisis. Approximately 2,004 sites, in compliance with a single expanded access protocol set forth by the US FDA, have been registered. Around 7,774 patients are engaged in this treatment process, and 3,809 of them have already received a convalescent plasma transfusion. Attention could potentially be drawn to experimental convalescent plasma therapy if enough supporting data is acquired.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report

Which Regions Are Becoming Hubs for COVID-19 Current Therapy Market Innovation?
North America is the largest region in the COVID-19 current therapy market in 2024. Middle East is expected to be the fastest-growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the COVID-19 current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the COVID-19 Current Therapy Market?
2. What is the CAGR expected in the COVID-19 Current Therapy Market?
3. What Are the Key Innovations Transforming the COVID-19 Current Therapy Industry?
4. Which Region Is Leading the COVID-19 Current Therapy Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.